Drug‐Induced Lupus

Abstract:  Drug‐induced lupus (DIL) is a rare adverse reaction to a large variety of drugs with features resembling those of idiopathic systemic lupus erythematosus (SLE). It usually develops only after months and, quite commonly, years of treatment with the offending agent, although latencies of days or weeks have been described in some instances. There are some indications that the risk of DIL can increase with higher daily and cumulative doses and with longer duration of therapy. There are no definitive and commonly accepted diagnostic criteria for DIL, but the following guidelines have been proposed: (a) sufficient and continuing exposure to a specific drug, (b) at least one symptom compatible with SLE, (c) no history suggestive of SLE before starting the drug, and (d) resolution of symptoms within weeks (sometimes months) after discontinuation of the putative offending agent. In addition, it is frequently suggested that the presence of ANA is required for the diagnosis of DIL. However, negative ANA test results should not automatically preclude such a diagnosis, particularly if a patient has other autoantibodies associated with SLE/DIL.

[1]  B. Noël.  Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  J. Szepietowski,et al.  Drug‐induced subacute cutaneous lupus erythematosus resulting from ticlopidine , 2006, International journal of dermatology.

[3]  A. R. Rätz Bravo,et al.  [Minocycline-induced lupus erythematodes]. , 2006, Praxis.

[4]  I. Litinsky,et al.  Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. , 2006, Seminars in arthritis and rheumatism.

[5]  E. Keystone,et al.  Musculoskeletal manifestations and autoimmune diseases related to new biologic agents , 2006, Current opinion in rheumatology.

[6]  Shannon W Finks,et al.  Hydralazine-induced Lupus: Maintaining Vigilance with Increased Use in Patients with Heart Failure , 2006, Southern medical journal.

[7]  J. Roujeau,et al.  Terbinafine-Induced Subacute Cutaneous Lupus Erythematosus , 2005, Dermatology.

[8]  D. Mevorach,et al.  Quinidine and procainamide inhibit murine macrophage uptake of apoptotic and necrotic cells: A novel contributing mechanism of drug-induced-lupus , 2005, Apoptosis.

[9]  S. Zorić,et al.  Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides , 2005, Arthritis research & therapy.

[10]  V. D’Agati,et al.  Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis , 2005 .

[11]  X. Mariette,et al.  Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey , 2005, Arthritis research & therapy.

[12]  A. del Rosso,et al.  Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. , 2005, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[13]  V. D’Agati,et al.  Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  E. Beutner,et al.  Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus , 2004, Lupus.

[15]  A. Zinsmeister,et al.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.

[16]  B. Richardson.  DNA methylation and autoimmune disease. , 2003, Clinical immunology.

[17]  K. Van Steen,et al.  Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. , 2003, Gastroenterology.

[18]  Zhiyong Zhang,et al.  Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. , 2003, Arthritis & Rheumatism.

[19]  R. Watson,et al.  Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. , 2003, Archives of dermatology.

[20]  A. Schnabel,et al.  Drug-induced lupus erythematosus by amiodarone. , 2002, Archives of internal medicine.

[21]  J. Carter,et al.  Antinuclear antibody-negative, drug-induced lupus caused by lisinopril. , 2001, Southern medical journal.

[22]  T. Luger,et al.  Terbinafine-induced subacute cutaneous lupus erythematosus. , 2001, Journal of the American Academy of Dermatology.

[23]  H. Lorenz,et al.  Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? , 2000, Arthritis and rheumatism.

[24]  R. Schlienger,et al.  Minocycline-Induced Lupus , 2000, Dermatology.

[25]  A. Kretz-Rommel,et al.  Disruption of positive selection of thymocytes causes autoimmunity , 2000, Nature Medicine.

[26]  R. Schlienger,et al.  Minocycline-induced lupus. A systematic review. , 2000, Dermatology.

[27]  R. Rubin.  Etiology and mechanisms of drug-induced lupus. , 1999, Current opinion in rheumatology.

[28]  M. Yaron,et al.  Minocycline-induced autoimmune syndromes: an overview. , 1999, Seminars in arthritis and rheumatism.

[29]  B. Stricker,et al.  Minocycline and lupuslike syndrome in acne patients. , 1999, Archives of internal medicine.

[30]  D. Mevorach,et al.  Systemic Exposure to Irradiated Apoptotic Cells Induces Autoantibody Production , 1998, The Journal of experimental medicine.

[31]  M. Sridhar,et al.  Fatal lupus-like syndrome and ARDS induced by fluvastatin , 1998, The Lancet.

[32]  K. Pramatarov.  Drug-induced lupus erythematosus. , 1998, Clinics in dermatology.

[33]  B. Ringertz,et al.  Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. , 1997, British journal of rheumatology.

[34]  S. Bastacky,et al.  Propylthiouracil-induced diffuse proliferative lupus nephritis: review of immunological complications. , 1997, Journal of the American Society of Nephrology : JASN.

[35]  J. Crosson,et al.  Minocycline-related lupus erythematosus with associated liver disease. , 1997, Journal of the American Academy of Dermatology.

[36]  A. Kretz-Rommel,et al.  Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus. , 1997, The Journal of clinical investigation.

[37]  E. Amento,et al.  Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. , 1996, The Journal of clinical investigation.

[38]  J. Alloway,et al.  Quinidine-induced rheumatic syndromes. , 1995, Seminars in arthritis and rheumatism.

[39]  B. Richardson,et al.  Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. , 1995, Journal of immunology.

[40]  G. Khursigara,et al.  Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. , 1994, Science.

[41]  D. Levison,et al.  Systemic lupus erythematosus-like syndrome with focal proliferative glomerulonephritis during D-penicillamine therapy. , 1993, British journal of rheumatology.

[42]  F. Dove.  Drug-induced lupus , 1982 .

[43]  J. Uetrecht,et al.  Metabolism of isoniazid by activated leukocytes. Possible role in drug-induced lupus. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[44]  R. Burlingame,et al.  Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. , 1991, The Journal of clinical investigation.

[45]  S. Spielberg,et al.  Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. , 1990, Molecular pharmacology.

[46]  B. Johansson,et al.  Effects of long-term treatment with procaine amide. A prospective study with special regard to ANF and SLE in fast and slow acetylators. , 2009, Acta medica Scandinavica.